Butyric Acid Protects Intestinal Epithelial Barrier from Injury Induced by TNFα

Luqiong LIU; Tong CHEN; Yongjin ZHANG; Zhenrong XIE; Chenglu HE; Yongkun HUANG

doi:10.12259/j.issn.2095-610X.S20231021

Volume 44 Issue 10

Oct. 2023

Turn off MathJax

Article Contents

Abstract

References

Relative Articles

Article Navigation > Journal of Kunming Medical University > 2023 > 44(10): 10-17

Huang Song Xia . The Effect of Evidence-based Care on the Complication Rate and Comfort in Patients with Coronary Heart Disease after Intervention Therapy[J]. Journal of Kunming Medical University, 2016, 37(06).

Citation:

Luqiong LIU, Tong CHEN, Yongjin ZHANG, Zhenrong XIE, Chenglu HE, Yongkun HUANG. Butyric Acid Protects Intestinal Epithelial Barrier from Injury Induced by TNFα[J]. Journal of Kunming Medical University, 2023, 44(10): 10-17. doi: 10.12259/j.issn.2095-610X.S20231021

Citation:

PDF( 3865 KB)

Butyric Acid Protects Intestinal Epithelial Barrier from Injury Induced by TNFα

doi: 10.12259/j.issn.2095-610X.S20231021

1.
Dept. of Pediatrics
2.
Scientific Research Laboratory Center
3.
The Medical Biobank
4.
Dept. of Laboratory Medicine，The 1st Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032，China

Received Date: 2023-06-15
Available Online: 2023-09-12
Publish Date: 2023-10-25

Abstract

Abstract

Objective To explore the protective effect of butyric acid on intestinal epithelial barrier damage induced by TNF α. Methods CCK-8 cell viability assay was used to determine the optimal concentration and time of TNFα in exerting damaged effects on Caco2 damage, and based on this, the protective effect of butyric acid on Caco2 cells was explored around the optimal time when TNFα exerted damage. Subsequently, the optimal time and concentration of TNFα and butyric acid acting on Caco2 cells were explored, and the FITC-dextran permeability of the Caco2 cell monolayer epithelial barrier, the mRNA expression of ZO-1 and Occludin, and the growth of cells after TNFα and butyric acid co-treatment were detected, as well as the expression and distribution of ZO-1 and Occludin in Caco2 cells were observed by immunofluorescence. Results TNFα, at a concentration of 100 ng/mL significantly decreased the cell viability of Caco2 after 48 hours of stimulation （P < 0.0001）; butyrate at a concentration of 0.2mM/L significantly increased the cell viability of Caco2 after 48 hours of treatment （P < 0.0001）. When TNFα and butyrate were co-administered, compared with the TNFα intervention group, butyrate significantly decreased the FITC-dextran permeability of the intestinal epithelial monolayer barrier caused by TNFα （P < 0.0001）, and increased the expression of ZO-1 （P < 0.01） and Occludin （P < 0.01）, and stabilized their distribution in Caco2 cells. Conclusion Butyrate can alleviate TNFα-induced damage to intestinal epithelial barrier, providing experimental basis for further elucidating the mechanism of butyrate in the treatment of ulcerative colitis.
- Caco2,
- Ulcerative colitis,
- TNF α,
- Butyric acid,
- ZO-1,
- Occludin

FullText(HTML)

References(22)

References

[1]	Zhang W,Lyu M,Bessman N J,et al. Gut-innervating nociceptors regulate the intestinal microbiota to promote tissue protection[J]. Cell,2022,185(22):4170-4189.e20. doi: 10.1016/j.cell.2022.09.008
[2]	Tan G,Huang C,Chen J,et al. An IRF1-dependent pathway of TNFα-induced shedding in intestinal epithelial cells[J]. J Crohns Colitis,2022,16(1):133-142. doi: 10.1093/ecco-jcc/jjab134
[3]	Abraham C,Abreu M T,Turner J R. Pattern recognition receptor signaling and cytokine networks in microbial defenses and regulation of intestinal barriers: Implications for inflammatory bowel disease[J]. Gastroenterology,2022,162(6):1602-1616.e6. doi: 10.1053/j.gastro.2021.12.288
[4]	Nguyen N H,Solitano V,Vuyyuru S K,et al. Proactive therapeutic drug monitoring versus conventional management for inflammatory bowel diseases: A systematic review and meta-analysis[J]. Gastroenterology,2022,163(4):937-949.e2. doi: 10.1053/j.gastro.2022.06.052
[5]	Matsuoka K,Kanai T. The gut microbiota and inflammatory bowel disease[J]. Semin Immunopathol,2015,37(1):47-55. doi: 10.1007/s00281-014-0454-4
[6]	Nighot M,Al-Sadi R,Guo S,et al. Lipopolysaccharide-induced increase in intestinal epithelial tight permeability is mediated by Toll-like receptor 4/Myeloid differentiation primary response 88 (MyD88) activation of myosin light chain kinase expression[J]. Am J Pathol,2017,187(12):2698-2710. doi: 10.1016/j.ajpath.2017.08.005
[7]	Yang J,Pei G,Sun X,et al. RhoB affects colitis through modulating cell signaling and intestinal microbiome[J]. Microbiome,2022,10(1):149-170. doi: 10.1186/s40168-022-01347-3
[8]	Foerster EG,Mukherjee T,Cabral-Fernandes L,et al. How autophagy controls the intestinal epithelial barrier[J]. Autophagy,2022,18(1):86-103. doi: 10.1080/15548627.2021.1909406
[9]	Xiong T,Zheng X,Zhang K,et al. Ganluyin ameliorates DSS-induced ulcerative colitis by inhibiting the enteric-origin LPS/TLR4/NF-κB pathway[J]. J Ethnopharmacol,2022,289(8):115001-115014.
[10]	Kumar A,Priyamvada S,Ge Y,et al. A Novel Role of SLC26A3 in the maintenance of intestinal epithelial barrier Integrity[J]. Gastroenterology,2021,160(4):1240-1255.e3. doi: 10.1053/j.gastro.2020.11.008
[11]	Guo H,Guo H,Xie Y,et al. Mo(3)Se(4) nanoparticle with ROS scavenging and multi-enzyme activity for the treatment of DSS-induced colitis in mice[J]. Redox Biol,2022,56(8):102441.
[12]	Wu X X,Huang X L,Chen R R,et al. Paeoniflorin prevents intestinal barrier disruption and inhibits lipopolysaccharide (LPS)induced inflammation in Caco2 cell monolayers[J]. Inflammation,2019,42(6):2215-2225. doi: 10.1007/s10753-019-01085-z
[13]	Beisner J,Filipe Rosa L,Kaden-Volynets V,et al. Prebiotic inulin and sodium butyrate attenuate obesity-induced intestinal barrier dysfunction by induction of antimicrobial peptides[J]. Front Immunol,2021,12:678360. doi: 10.3389/fimmu.2021.678360
[14]	Kim JT,Napier DL,Kim J,et al. Ketogenesis alleviates TNFα-induced apoptosis and inflammatory responses in intestinal cells[J]. Free Radic Biol Med,2021,172:90-100. doi: 10.1016/j.freeradbiomed.2021.05.032
[15]	Nakase H,Sato N,Mizuno N,et al. The influence of cytokines on the complex pathology of ulcerative colitis[J]. Autoimmun Rev,2022,21(3):103017. doi: 10.1016/j.autrev.2021.103017
[16]	Song G,Gan Q,Qi W,et al. Fructose stimulated colonic arginine and proline metabolism dysbiosis,altered microbiota and aggravated intestinal barrier dysfunction in DSS-induced colitis rats[J]. Nutrients,2023,15(3):782-798. doi: 10.3390/nu15030782
[17]	Greuter T,Rieder F,Kucharzik T,et al. Emerging treatment options for extraintestinal manifestations in IBD[J]. Gut,2021,70(4):796-802. doi: 10.1136/gutjnl-2020-322129
[18]	Li G,Lin J,Zhang C,et al. Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease[J]. Gut Microbes,2021,13(1):1968257-1968275. doi: 10.1080/19490976.2021.1968257
[19]	Gasaly N,Hermoso M A,Gotteland M. Butyrate and the fine-tuning of colonic homeostasis: Implication for inflammatory bowel diseases[J]. Int J Mol Sci,2021,22(6):3061-3078. doi: 10.3390/ijms22063061
[20]	Benvenuti L,D'Antongiovanni V,Pellegrini C,et al. Dietary supplementation with the probiotic SF68 reinforces intestinal epithelial barrier in Obese mice by improving butyrate bioavailability[J]. Mol Nutr Food Res,2023,67(13):e2200442. doi: 10.1002/mnfr.202200442
[21]	Facchin S,Vitulo N,Calgaro M,et al. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease[J]. Neurogastroenterol Motil,2020,32(10):e13914.
[22]	Jourova L,Satka S,Frybortova V,et al. Butyrate treatment of DSS-induced ulcerative colitis affects the hepatic drug metabolism in mice[J]. Front Pharmacol,2022,13:936013. doi: 10.3389/fphar.2022.936013

Relative Articles(20)

Relative Articles

[1]	Hanyu ZHANG, Juan LUO, Mingzhi DONG, Qiyin CHEN, Fengrui ZHANG, Rui GUO, Junying TONG, Yinglei MIAO. Retrospective Cohort Study of Infliximab and Vederizumab in the Treatment of Moderate-to-severe Ulcerative Colitis. Journal of Kunming Medical University, 2025, 46(4): 1-9.
[2]	Hanyu ZHANG, Juan LUO, Mingzhi DONG, Qiyin CHEN, Fengrui ZHANG, Rui GUO, Junying TONG, Yinglei MIAO. Retrospective Cohort Study of Infliximab and Vederizumab in the Treatment of Moderate-to-severe Ulcerative Colitis. Journal of Kunming Medical University, 2024, 45(10): 36-44. doi: 10.12259/j.issn.2095-610X.S20241006
[3]	Chunling LI, Linghua LI, Xu HAN, Jie YANG, Heng ZHANG. Clinical Observation of Treating Ulcerative Colitis with Acupuncture at Front Mu Points Combined with Oral Mesalazine. Journal of Kunming Medical University, 2024, 45(3): 72-78. doi: 10.12259/j.issn.2095-610X.S20240311
[4]	Meizi RAO, Xinyi JIANG, Jiarong MIAO. Analysis of Risk Factors for Co-Infection of Ulcerative Colitis with Epstein-barr Virus and Cytomegalovirus. Journal of Kunming Medical University, 2024, 45(11): 87-94. doi: 10.12259/j.issn.2095-610X.S20241113
[5]	Jing WANG, Hongying MI, Yi ZHANG, Li LI, Jianhua YU, Liqiao LIU, Qingyu LIU, Liwei WANG. Pyrotosis Participates in the Pathogenesis of Necrotizing Enterocolitis in Early Offspring Rats. Journal of Kunming Medical University, 2023, 44(1): 25-30. doi: 10.12259/j.issn.2095-610X.S20230124
[6]	Guili LIANG, Canmei LI, Chengfeng XING, Yunlong DONG, Juan WANG, Zi LEI, Yinglei MIAO, Danfeng LAN. Changes of Intestinal Inflammatory Injury Induced by DSS in GC-C^-/- Mice. Journal of Kunming Medical University, 2022, 43(7): 1-8. doi: 10.12259/j.issn.2095-610X.S20220712
[7]	Xiaolin LIU, Xiaocui CHEN, Yang SUN, Minli LI, Yinglei MIAO. Clinical Efficacy and Safety Evaluation of Fecal Bacteria Transplantation by Different Ways on Ulcerative Colitis. Journal of Kunming Medical University, 2022, 43(6): 46-51. doi: 10.12259/j.issn.2095-610X.S20220612
[8]	Jing WANG, Lian-fang TANG, Mei-qun GU, Xiao-yan XU, Jian-hua YU, Shan HE, Zi-wei LI, Kai BI, Li-qiao LIU, Qiong ZHAO, Hong-ying MI. Risk Factors and Early Clinical Characteristics of Neonatal Necrotizing Enterocolitis. Journal of Kunming Medical University, 2021, 42(11): 99-104. doi: 10.12259/j.issn.2095-610X.S20211118
[9]	Ma Chen Li , Yang Gen Meng , Yan Qing Wen , Zhang Feng Yi , Shi Zhen Jin , Zhou Yi Qing , Wang Yi Hang , Zhao Yong Na , Zhang Dong Xian , Li Li Hua , Hong Shi Jun . Expression of Astrocyte, Neuron, and Proinflammatory Cytokines Derived from Frontal Cortex of Methamphetamine Dependent rats after Gastrodin Administration. Journal of Kunming Medical University, 2018, 39(06): 1-6.
[10]	Meng Guo Yi , Sui Nian Han , Yang Jin Feng , Bian Li Gong , Hong Shi Jun , Li Li Hua , Zhao Yong Na . . Journal of Kunming Medical University, 2017, 38(02): 19-22.
[11]	Huang Song Jing , Lei Ya Yan , She Rui , Wu Jian Hua , Liu Shu Mei , Zhang Ming Zhu . Effect of Yunnan Baiyao on the Secretion of TNF-α, IL-6, IL-1β from Human Dental Pulp Cells under LPS-PG induced Inflammatory Environment. Journal of Kunming Medical University, 2017, 38(08): 73-78.
[12]	Ai Bao . Correlation between Serum Levels of Melatonin TNF-Αand EDSS Scores in Multiple Sclerosis Patients. Journal of Kunming Medical University,
[13]	Li Jun Jie . The Gene Expression Change of Inflammatory Factors TNF-α， IL-6 and IL-1βin Cerebral Ischemia-Reperfusion Rats. Journal of Kunming Medical University,
[14]	Chen Xiao Hong . Influence of Continuous Nursing Intervention on Psychological Quality and Medication Compliance in Ulcerative Colitis Patients after Discharge. Journal of Kunming Medical University,
[15]	Li Yu Huan . . Journal of Kunming Medical University,
[16]	Ai Jia . . Journal of Kunming Medical University,
[17]	Li Hong Li . . Journal of Kunming Medical University,
[18]	Ju Hong Ping . . Journal of Kunming Medical University,
[19]	. The Dynamic Changes of TNF-α, β-EP and IL-10 in the Plasma of Rats after Severe Trauma. Journal of Kunming Medical University,
[20]	Yang Fang . . Journal of Kunming Medical University,